Soticlestat is an investigational oral cholesterol 24-hydroxylase (CH24H) inhibitor designed to modulate brain cholesterol metabolism and neuronal activity, offering a potential therapeutic approach for… Read more
Soticlestat is an investigational oral cholesterol 24-hydroxylase (CH24H) inhibitor designed to modulate brain cholesterol metabolism and neuronal activity, offering a potential therapeutic approach for neurodegenerative disorders such as Alzheimer's disease. Within this category, researchers and pharmaceutical laboratories can access essential reference standards, including the active pharmaceutical ingredient (API), pharmacopeial and non-pharmacopeial impurities, and stable isotope-labelled compounds. These high-quality materials are critical for rigorous impurity profiling, structural characterization, and method validation during the drug development process. By utilizing these precisely defined standards, analytical chemists can ensure accurate quantification and consistent quality control, supporting the regulatory compliance and safety evaluation required for emerging therapeutic candidates. This comprehensive selection facilitates the reliable analysis of Soticlestat throughout the various stages of pharmaceutical research and development.